Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Praxis Precision Medicines (PRAX) and Eli Lilly & Co...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Eli Lilly & Co (LLY)

Holley ( ($HLLY) ) has issued an announcement. On May 26, 2026, Holley Inc. announced that its Board of Directors approved a share repurchase progr...

Holley Board Authorizes $25 Million Share Repurchase Program

In a report released on May 24, David Bailey from Morgan Stanley reiterated a Buy rating on CSL, with a price target of $166.00. According to TipRa...

CSL (CMXHF) Receives a Buy from Morgan Stanley

Bristol Gate Capital Partners Inc., managed by Richard Hamm, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). ...

Bristol Gate Capital trims Eli Lilly stake by 4,966 shares

Mirova US LLC, managed by Philippe Zaouati, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The hedge fund re...

Mirova US LLC Cuts Eli Lilly Stake by 15,836 Shares

ARK Investment Management LLC, managed by Cathie Wood, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The he...

ARK Investment’s Cathie Wood boosts Eli Lilly stake by 12,676 shares

Graham Capital Management, L.P., managed by Kenneth Tropin, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). T...

Graham Capital Management Boosts Eli Lilly Stake by 1,869 Shares

Ardsley Advisory Partners, managed by Philip Hempleman, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The h...

Ardsley Advisory Partners Cuts 35,000 Eli Lilly Shares

Chilton Investment Co LLC, managed by Richard Chilton, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The he...

Chilton Investment Trims Eli Lilly Stake, Sells 4,088 Shares

Moore Capital Management LP, managed by Louis Moore Bacon, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). Th...

Moore Capital trims Eli Lilly stake, sells 11,000 shares

Mairs & Power Inc, managed by Bill Frels, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The hedge fund redu...

Mairs & Power Inc Cuts Eli Lilly Stake by 19,039 Shares

Bridgewater Associates, LP, managed by Ray Dalio, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The hedge f...

Bridgewater Associates, LP Trims Eli Lilly Stake by 2,480 Shares

Woodline Partners LP, managed by Michael Rockefeller, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The hed...

Woodline Partners LP Boosts Eli Lilly Stake by 17,612 Shares

PRIMECAP Management Co, managed by Theofanis Kolokotrones, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). Th...

PRIMECAP Management Co trims Eli Lilly stake by 42K shares

Gamco Investors, Inc. ET AL, managed by Mario Gabelli, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The he...

Gamco Investors’ Mario Gabelli Boosts Eli Lilly Stake

Eli Lilly & Co ( ($LLY) ) has risen by 7.78%. Read on to learn why. Eli Lilly & Co shares climbed 7.78% over the past week as investors focused


Eli Lilly & Co Surges on Powerful Pipeline Hopes

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company (LLY) has launched a Phase ...

Eli Lilly Expands Heart Failure Pipeline With New Phase 1 Trial of LY3971297

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edwards Lifesciences (EW) and Eli Lilly & Co (LLY) w...

Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Eli Lilly & Co (LLY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and IN8bio (INAB) with bullish ...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and IN8bio (INAB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Arvinas Holding Company (AR...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN)

Eli Lilly stock still has major upside potential, according to one top analyst.


How High Can Eli Lilly’s Stock (LLY) Price Go?

The company has a growing number of obesity medications. 


Eli Lilly’s (LLY) Next-Generation Weight-Loss Drug Clears Big Hurdle

Using the TipRanks Stock Screener Tool, we identified three companies that have low Price-to-Earnings (P/E) ratios and hold a “Strong Buy” consensu...

3 ‘Strong Buy’ Low P/E Stocks with Over 20% Upside

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY), Zai Lab (ZLAB) and NanoViricides (NNVC). El...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zai Lab (ZLAB) and NanoViricides (NNVC)

Eli Lilly & Co ( ($LLY) ) has provided an update. On May 20, 2026, Eli Lilly and Company completed a multibillion-dollar debt offering, issuing a m...

Eli Lilly Raises $8.9 Billion in Debt Offering

Bristol Myers Squibb ($BMY), a large U.S. drug firm focused on cancer, blood, and immune disease drugs, is teaming up with Anthropic to bring its C...

BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees

Traders will find the hottest stock market stories from Wednesday in our daily wrap-up.


Morning News Wrap-Up, 5/19/26: Today’s Biggest Stock Market Stories!

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 1 trial titled “A Phase 1, Open-Label, Fixed-Sequence S...

Eli Lilly Completes Key Olomorasib Drug Interaction Study, Clarifying Next Steps for KRAS Pipeline

U.S. President Donald Trump bought $680,000 of Eli Lilly ($LLY) stock around the time that the U.S. Food and Drug Administration (FDA) approved the...

President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill

Investors will find the top stock market stories for Monday ready to go in our daily wrap-up.


Morning News Wrap-Up, 5/18/26: Today’s Biggest Stock Market Stories!

Shares of Dell ($DELL) are down today despite the tech firm announcing that it added 1,000 new customers for its AI Factory product line last quart...

Dell Stock Slides despite Adding 1,000 New Enterprise AI Customers

Shares in drugmakers Pfizer ($PFE), Eli Lilly ($LLY), and Novo Nordisk ($NVO) edged lower on Monday afternoon after CNBC’s Megan Cassella revealed ...

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

Eli Lilly ($LLY) has become the face of the global obesity drug boom, powered by its GLP-1 (glucagon-like peptide-1) based tirzepatide franchises M...

Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?

Barclays analyst Emily Field maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,400.00. Field covers the Healthcare secto...

Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Citi analyst Laura Sutcliffe maintained a Hold rating on CSL today and set a price target of A$110.00. According to TipRanks, Sutcliffe is a 3-star...

Citi Sticks to Its Hold Rating for CSL (CMXHF)

The pharma company has a best-selling weight-loss pill on its hands. 


Jim Cramer Sees a ‘Bull Market’ for Eli Lilly Stock (LLY)

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) is running a midstage trial of LY4005130 ...

Eli Lilly’s New Alopecia Drug Trial Moves Forward, Expanding Its Immunology Pipeline

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 2 trial “A Study of LY4005130 in Adult Participants Wit...

Lilly’s New Vitiligo Trial Signals Fresh Optionality in Immuno-Dermatology

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) is running a Phase 2 study called “A Phas...

Lilly’s Brenipatide IBS-C Trial Advances: What Investors Should Watch

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is running a Phase 2 trial called “A ...

Eli Lilly Expands GI Pipeline With New Phase 2 Brenipatide Trial in IBS-D

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company has launched a long term extension study ca...

Lilly Extends ALS Pipeline With New Long-Term Safety Trial for LY4256984

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 2 study “A Study to Investigate Weight Management With ...

Lilly’s New Obesity Pill Trial Completes: What LY3549492 Could Mean for LLY Investors

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 3b TOGETHER-PsA trial, officially titled “Efficacy and ...

Lilly Tests Dual Psoriatic Arthritis and Obesity Strategy With Ixekizumab–Tirzepatide Combo

In a report released on May 12, Aymeric Poulain from Kepler Capital maintained a Buy rating on Thales, with a price target of €320.00. The company’...

Kepler Capital  Sticks to Its Buy Rating for Thales (0IW5)

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Eli Lilly & Co, with a price target of $1,300.00. According ...

BMO Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Traders seeking the top stock market stories for Tuesday will find them in our roundup.


Morning News Wrap-Up, 5/12/26: Today’s Biggest Stock Market Stories!

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 4 study titled “A Phase 4, Open-Label, Single-Arm, 46-W...

Eli Lilly Extends Tirzepatide Push With New Phase 4 Study in India

In a report released today, Derek Jellinek from Morgans maintained a Buy rating on CSL, with a price target of A$147.59. According to TipRanks, Jel...

CSL (CMXHF) Receives a Buy from Morgans

In a report released today, Thomas Wakim from Bell Potter maintained a Hold rating on CSL, with a price target of A$100.00. According to TipRanks, ...

CSL (CMXHF) Receives a Hold from Bell Potter

Macquarie analyst Christine Trinh maintained a Hold rating on CSL today and set a price target of A$176.00. According to TipRanks, Trinh is ranked ...

Macquarie Sticks to Their Hold Rating for CSL (CMXHF)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aardvark Therapeutics, Inc. (AARD), Prothena (PRTA...

Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Prothena (PRTA) and Eli Lilly & Co (LLY)

Last week, stocks pushed to fresh highs as strong jobs data and gains in chip stocks helped lift the market. The S&P 500 (SPX) rose 0.84% to 7,397....

The Week That Was, The Week Ahead: Macro and Markets, May 10

Insiders have been trading these 5 stocks: (($JPM)), (($CVX)), (($LLY)), (($BRK.B)) and (($MSTR)). Here is a breakdown of their recent trades and t...

Insider Frenzy at JPMorgan, Chevron, Eli Lilly, Berkshire, Strategy

Vanguard S&P 500 ETF ($VOO) remains one of the most popular choices for investors seeking broad exposure to the U.S. stock market. However, as mark...

Looking Beyond VOO? These 3 BlackRock ETFs Offer 20%+ Upside in 2026

Traders will find all of the latest earnings, analysts, and economic news in our daily wrap-up.


Morning News Wrap-Up, 5/7/26: Today’s Biggest Stock Market Stories!

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Becton Dickinson (BDX), Immunocore Holdings (IMCR) and Eli Lilly ...

Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Immunocore Holdings (IMCR) and Eli Lilly & Co (LLY)

Amazon ($AMZN) is adding Novo Nordisk ($NVO)’s Ozempic pill to Amazon Pharmacy, as it builds a deeper role in the fast-growing market for GLP-1 dru...

Amazon (AMZN) Targets GLP-1 Growth with Novo’s Ozempic Pill

Hims & Hers Health ($HIMS) will report its Q1 2026 earnings on May 11. The telehealth company heads into earnings with strong recent momentum, with...

HIMS Stock Forecast — What Financial Analysts Expect Ahead of Q1 Earnings

There’s a lot to be optimistic about in the Consumer Cyclical sector as 2 analysts just weighed in on Holley (HLLY) and Steven Madden (SHOO) with b...

Wall Street Analysts Are Bullish on Top Consumer Cyclical Picks

Holley ( ($HLLY) ) has issued an announcement. On May 1, 2026, Holley Inc. held its 2026 Annual Meeting of Stockholders, at which shareholders elec...

Holley shareholders approve proposals at 2026 annual meeting

Novo Nordisk ($NVO), maker of the popular weight-loss drug Wegovy, saw its shares move higher on Wednesday after reporting stronger-than-expected f...

Novo Nordisk Earnings: NVO Stock Rises as Wegovy Sales Drive Massive Q1 Beat

Value stocks are shares of companies that appear undervalued relative to their fundamentals. This means their stock price looks low compared with w...

3 Best Value Stocks to Buy in May 2026, According to Analysts 

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Tenet Healthcare (THC) with...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Magna International (MGA) and Holley (HLLY)...

Analysts Offer Insights on Consumer Cyclical Companies: Magna International (MGA) and Holley (HLLY)

Last week, stocks held near highs as gains in tech helped offset mixed macro news. The S&P 500 ($SPY) rose 0.29% to 7,230, while the Nasdaq (NDX) g...

The Week That Was, The Week Ahead: Macro and Markets, May 3

Eli Lilly & Co ( ($LLY) ) has risen by 10.95%. Read on to learn why. Eli Lilly & Co shares have climbed 10.95% over the past week, as investors


Eli Lilly & Co Soars on Obesity-Drug Power Play

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) an...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) and TELA Bio (TELA)

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Eli Lilly & Co, with a price target of $1,281.00....

Truist Financial Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,500.00. Meacham covers the Healthcare secto...

Citi Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Traders will find the most recent earnings reports, analysts updates, and economic data at TipRanks.


Morning News Wrap-Up, 4/30/26: Today’s Biggest Stock Market Stories!

Here’s a look at today’s key earnings reports from major publicly traded companies. Stock market investors will undoubtedly be watching closely for...

These Are the Stocks Reporting Earnings Today – April 30, 2026

Shares in drugmakers Eli Lilly ($LLY) and Novo Nordisk ($NVO) climbed on Thursday morning after the U.S. health watchdog proposed not to allow outs...

Eli Lilly, Novo Nordisk Stocks Jump as FDA Moves Against Bulk Production of Obesity Drug Ingredients

The latest announcement is out from Nelly Group AB ( ($SE:NELLY) ). Nelly Group AB has marginally increased its share capital after 24,606 ordinary...

Nelly Group Marginally Increases Share Capital After Warrant Exercise

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Crescent Biopharma (CBIO) and ...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Crescent Biopharma (CBIO) and Guardant Health (GH)

TipRanks has collected a list of the biggest stock market stories investors need to read on Wednesday.


Morning News Wrap-Up, 4/29/26: Today’s Biggest Stock Market Stories!

Cheaper generic obesity drugs are expected to compete against name brand versions.  


Eli Lilly Stock (LLY) Falls as Canada Approves Generic Weight-Loss Drugs

The latest announcement is out from Nelly Group AB ( ($SE:NELLY) ). Nelly Group AB reported first-quarter 2026 net revenue of SEK 243.3 million, a ...

Nelly Group Posts Margin Gains but Softer Profits Amid CFO Transition in Q1 2026

Traders will find the top stock market stories for Monday in our daily wrap-up.


Morning News Wrap-Up, 4/27/26: Today’s Biggest Stock Market Stories!

Pharmaceutical giant Eli Lilly ($LLY) remains on a buying spree, announcing that it is acquiring cancer drug developer Ajax Therapeutics for $2.3 b...

Eli Lilly (LLY) Continues Buying Spree with $2.3 Billion Purchase of Ajax Therapeutics

SoFi Technologies ($SOFI) is entering what could be its most important earnings moment yet, as the company looks to prove its transition from a los...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$1,079.39	+1.35%	1.15M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$1,079.39	+1.4%	1.15M
3
4
5
6

LLY

LLY

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel